Interim clinical commissioning policy statement: Teriparatide for osteoporosis in men (adults)

NHS England have extended the routine commissioning of teriparatide in osteoporosis to include use in men; in line with the criteria in NICE TA161 (teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women).

SPS commentary:

NICE will be developing guidance on non-bisphosphonate treatment of osteoporosis.

NICE TA161 (Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women)

NHS England